Drug delivery system successfully treats deadly ovarian cancer in mice

December 6, 2013 by Robin Lally
Drug delivery system successfully treats deadly ovarian cancer in mice
Rutgers' scientists believe that a out of control protein is what makes late-stage ovarian cancer resistant to drug treatment. Credit: Shutterstock

(Medical Xpress)—Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer in the United States.

Tamara Minko, professor in the Ernest Mario School of Pharmacy, and Lorna Rodriguez, professor of obstetrics, gynecology and reproductive sciences at Robert Wood Johnson Medical School, say because there is not a good screening method for ovarian , most women with the disease are not diagnosed until after it has metastasized to other organs and surgery and chemotherapy are not as effective.

"Once the ovarian cancer becomes drug resistant we cannot cure it," says Rodriguez a gynecologic oncologist who provides treatment to ovarian cancer patients and is director of the precision medicine initiative at Rutgers Cancer Institute of New Jersey. "Circumventing the development of drug resistance is a reasonable approach and very much needed."

The main reason for advanced-stage ovarian cancer, they say, is an out of control protein CD44, which enables to proliferate and become resistant to conventional drug treatments. The result: a five-year survival rate for patients with advanced-stage ovarian cancer that is only 30 percent.

In a new study published in Clinical Cancer Research, Minko and Rodriguez provide results of animal research in which the cancer is attacked at the genetic level by using small, inhibiting RNA molecules that directly target and decrease the excess CD44 protein in while simultaneously treating patients with the anti-cancer drug paclitaxel. This allows cells within the cancerous tumors to be successfully treated even at an advanced stage.

"We expect that the proposed treatment will be especially effective in advanced stages of , where there are many cancer stem cells in the tumors that resist conventional drug treatment," says Minko.

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory mice. They then used a combination of chemotherapy and gene therapy to target the cancer cells directly in order to inhibit growth and prevent metastasis while sparing normal healthy cells. The treatment killed cancerous in the mice, shrunk their tumors and left them with fewer side effects.

Since the CD44 protein is expressed on the surface of many , the approach developed by Rutgers scientists may help in the treatment of other types of cancers. The next step for ovarian cancer research would be to develop a for human consumption that could be used in clinical trials. This, they say, could lead to new pharmacological cancer treatments and increase the survival rate of the deadly disease.

Explore further: New ovarian cancer treatment succeeds in the lab

More information: "Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug." Vatsal Shah, Oleh Taratula, Olga B. Garbuzenko, Olena R. Taratula, Lorna Rodriguez-Rodriguez, and Tamara Minko. Clin Cancer Res November 15, 2013 19:6193-6204; Published OnlineFirst September 13, 2013; DOI: 10.1158/1078-0432.CCR-13-1536

Related Stories

New ovarian cancer treatment succeeds in the lab

October 17, 2013
In a study to be published today in Scientific Reports, researchers from the Florida International University Herbert Wertheim College of Medicine and the FIU College of Engineering and Computing describe what could be a ...

New drug extends life in women with advanced ovarian cancer

November 5, 2013
Women with ovarian cancer that has returned after previous treatment had their life extended by almost three months after treatment with a drug called Cediranib, according to trial results presented today at the National ...

Biomarkers predict time to ovarian cancer recurrence

August 15, 2013
Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated ...

Inhalation therapy for lung cancer shows promise in study

June 10, 2013
(Medical Xpress)—Lung cancer kills about 1.5 million men and women around the world – more than the number of people who die from breast, colon, pancreatic and prostate cancers combined.

New method to sensitize human ovarian cancer cells to a targeted cytotoxic drug

May 29, 2013
A novel, targeted approach to chemotherapy that makes ovarian cancer cells more susceptible to the cytotoxic effects of an antitumor drug may offer a safer, more effective treatment option for this often deadly form of cancer. ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.